This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn has ...
Shares of pharmaceutical company Bristol Myers Squibb ($BMY) are up 4% on news that the U.S. Food and Drug Administration ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $50.12.
Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
The indictment accuses the mayor of accepting and seeking “illegal campaign contributions to his 2021 mayoral campaign, as well as other things of value, from foreign nationals.” Hurubie Meko ...
Eric Adams Awaits Arraignment in Court on Bribery and Fraud Charges The New York mayor was scheduled to be arraigned today. He has insisted he will stay in office and asked New Yorkers to give him ...